MedPath

Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)

Not Applicable
Recruiting
Conditions
Severe Dengue
Interventions
Drug: Placebo
Registration Number
NCT05631405
Lead Sponsor
Chulalongkorn University
Brief Summary

The goal of this randomized double-blinded placebo-controlled trial is to learn about dexamethasone and the treatment of severe dengue population. The main question it aims to answer are steroid therapy may be effective in dengue.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Laboratory confirmed Dengue infected patients (Positive NS1 Ag or anti-DENV IgM by Dengue Duo test)
  • And still in febrile phase (Body temp>37.5 C)
  • Shock : Sys<90mmHg or Narrow PP (<20mmHg) orTachycardia (pulse>100/min) with Hematocrit decreased ≥20 %
  • Fluid accumulation and respiratory distress
  • Severe bleeding
  • Severe organ involvement
Exclusion Criteria
  • Severe dengue> 24 hrs
  • Dengue without warning signs
  • Pregnancy
  • Patient who receieved any steroid within 1 week

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
InterventionDexamethasone-
Primary Outcome Measures
NameTimeMethod
Mortality28 days

The use of steroids in dengue will reduce mortality in rate

Secondary Outcome Measures
NameTimeMethod
Length of hospital stay28 days

The use of steroids in dengue will reduce Length of hospital stay in day

Trial Locations

Locations (2)

Chulalongkorn University

🇹🇭

Bangkok, Thailand

King Chulalongkorn Memorial Hospital

🇹🇭

Bangkok, Thailand

© Copyright 2025. All Rights Reserved by MedPath